ArticleScientific reports2025
A pilot exploratory study for analysis of clinical features and plasma catecholamines in blepharospasm.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Blepharospasm (BSP) is a common focal movement disorder linked to the basal ganglia and plasma catecholamines (CAs). This study aimed to analyze clinical characteristics of BSP patients and explore the relationship with plasma CAs. Clinical characteristics, clinician-rated scales, and plasma CAs were recorded, including dopamine (DA), 3-methoxytyramine (3-MT), and the 3-MT/DA ratio. Plasma CA levels were measured using liquid chromatography-tandem mass spectrometry. Clinical features, plasma CAs, and metabolite contents were compared between groups. Spearman's correlation analysis examined the relationship between plasma CA levels, metabolites, and severity of BSP symptoms. We found that dry eye was an independent risk factor for BSP. Coffee consumption history was an independent protective factor against BSP. Compared to healthy controls, patients had increased DA and decreased 3-MT and 3-MT/DA levels. Anxiety severity negatively correlated with 3-MT and 3-MT/DA levels. The decreased 3-MT/DA ratio is more likely to be a potential biomarker of BSP. These findings highlight the importance of abnormal DA metabolism in BSP pathophysiology and suggest that anxiety symptoms may contribute to BSP pathogenesis by affecting CAs, providing new perspectives for future diagnosis, treatment, and prognostic evaluation of BSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.